![Banner_OffTargetEffectswithMattGline[92].png](https://static.wixstatic.com/media/08e71b_ed7fd1cb3b434626b72445ef0ed7b81c~mv2.png/v1/fill/w_763,h_291,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Banner_OffTargetEffectswithMattGline%5B92%5D.png)
About the show: Matt shares a biotech CEO's perspective on the news, and he interviews other leaders about management topics important to navigating the business of drug development.
About Matt
Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.
Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.
Episodes
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.